More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing…
View More PARP inhibitor shrinks tumors in pancreatic cancer patients with mutations
Home »
36% of proton pump inhibitor prescriptions for older adults may be unnecessary
One in eight older adults was prescribed proton pump inhibitor drugs, which are used to…
View More 36% of proton pump inhibitor prescriptions for older adults may be unnecessary
SGLT-2 inhibitor use not linked to increased risk for UTI events
(HealthDay)—Initiation of therapy with sodium-glucose cotransporter-2 (SGLT-2) inhibitors for type 2 diabetes mellitus is not…
View More SGLT-2 inhibitor use not linked to increased risk for UTI events
Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305
STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company…
View More Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305